VesSenDrugDeliv · A versatile platform for the design of targeting drug delivery vesicles

A versatile platform for the design of targeting drug delivery vesicles

Even though great progress has been made in the understanding of fundamental cancer biology and cancer therapy, the translation from fundamental research to advances in clinic is yet to be better addressed. One of the major issues is to selectively deliver the therapeutic cargos to the desired target so that collateral damage can be minimized. The project “A Versatile Platform for the Design of Targeting Drug Delivery Vesicles”, abbreviated “VesSenDrugDeliv”, was to discover a versatile molecular platform that can be used to co-assemble with various functional moieties in aqueous solution to prepare efficient targeting drug delivery nanoparticles. By doing so, we aimed to use this type of nanoparticles to increase the targeting selectivity and enhance the therapeutic efficacy toward targeted tumour cells. Significant transfer of knowledge was involved during my stay at Imperial College London sponsored by this MSCA-IF fellowship. This includes the training acquired in using the-state-of-the-art facility such as transmission electron microscope (TEM), scanning electron microscope (SEM) and circular dichroism (CD). There were great opportunities of building-up worldwide collaboration with top scientists from UK, France and Australia. I was also able to develop invaluable supervision and management skills when mentoring master and Ph.D. students with different background. Moreover, the multinational culture and multidisciplinary environment at the Stevens Group at has fully supported the multidisciplinary “VesSenDrugDeliv” project.

Data: CORDIS, © European Union